New Study Shows Probiotic Strain Effective in Improving Irritable Bowel Syndrom...(s in just two of the weekly abdominal pa...),Health

Date:3/24/2009

s in just two of the weekly abdominal pain measurements and saw no statistically significant effect in bloating. "This study helps confirm that Bacillus coagulans is effective in IBS," said Larysa Hun, M.D., author of the 44 subject study. "A combination of Bacillus coagulans, Lactobacillus acidophilus, and Streptococcus thermophilus was previously shown in a clinical trial to significantly improve IBS symptoms, but it was not possible to determine what effect, if any, each strain had by itself."

IBS is associated with impaired quality of life, psychiatric problems, family disruption, impaired workplace performance, unnecessary tests and surgery, high direct and indirect costs, and even death due to IBS medications or interventions. "IBS is the most common functional gastrointestinal disorder (FGID) and represents a tremendous public health problem," noted Nicholas Talley, M.D., Ph.D., of the Mayo Clinic, an expert on IBS and author of a scientific review article about the impact FGIDs have on society.

Two drugs, alosetron and lubiprostone, are FDA-approved only for certain types of IBS: alosetron is for women with severe IBS-related diarrhea only and has serious potential side effects; lubiprostone is only for women with IBS-related constipation. Doctors commonly recommend over-the-counter medications such as laxatives, antidiarrheals, and bulking agents for IBS. But in a recent interview, Talley said, "they don't work well for most people with IBS."

"We know from consumer data that people who try Digestive Advantage Irritable Bowel Syndrome are more likely to become repeat purchasers of the product than people who try 30 other of the most popular brands of digestive products sold in stores," said Marshall Fong, vice president of marketing at Ganeden Biotech, which helped fund the study through a research grant. "This study
'/>"/>

SOURCE Ganeden Biotech Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Phase IV Multi-center Clinical Study of Kutai Concludes in Nanjing
2. Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients
3. CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals
4. Results From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
5. MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
6. PSA Screening Cuts Deaths by 20%, Says Worlds Largest Prostate Cancer Study
7. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
8. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
9. New Study Suggests Cholesterol-Lowering Statins Reduce Severe Asthma Attacks that Result in Hospitalizations and Emergency Room Visits
10. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
11. Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study